 Joan O'Keefe
Concepts (128)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ataxia | 7 | 2020 | 79 | 4.300 |
Why?
| | Fragile X Syndrome | 8 | 2020 | 178 | 4.190 |
Why?
| | Tremor | 7 | 2020 | 136 | 4.120 |
Why?
| | Postural Balance | 4 | 2021 | 127 | 1.580 |
Why?
| | Gait | 6 | 2020 | 395 | 1.510 |
Why?
| | Fragile X Mental Retardation Protein | 5 | 2016 | 107 | 1.490 |
Why?
| | Accidental Falls | 3 | 2020 | 118 | 1.470 |
Why?
| | Gait Disorders, Neurologic | 3 | 2020 | 150 | 1.370 |
Why?
| | Heterozygote | 4 | 2020 | 115 | 1.310 |
Why?
| | Psychomotor Performance | 2 | 2020 | 258 | 0.860 |
Why?
| | Databases, Factual | 2 | 2021 | 391 | 0.850 |
Why?
| | Walking | 2 | 2022 | 249 | 0.840 |
Why?
| | Cytidine Diphosphate Choline | 1 | 2020 | 4 | 0.770 |
Why?
| | Nootropic Agents | 1 | 2020 | 14 | 0.760 |
Why?
| | Huntington Disease | 1 | 2020 | 61 | 0.720 |
Why?
| | Attention | 1 | 2020 | 163 | 0.720 |
Why?
| | Phenotype | 3 | 2016 | 379 | 0.710 |
Why?
| | Movement Disorders | 2 | 2020 | 150 | 0.700 |
Why?
| | Cyclodextrins | 1 | 2018 | 7 | 0.660 |
Why?
| | Niemann-Pick Disease, Type C | 1 | 2018 | 17 | 0.650 |
Why?
| | Executive Function | 1 | 2018 | 109 | 0.650 |
Why?
| | Male | 17 | 2021 | 17583 | 0.630 |
Why?
| | Severity of Illness Index | 3 | 2020 | 1240 | 0.580 |
Why?
| | Female | 16 | 2021 | 18253 | 0.580 |
Why?
| | Receptors, Estrogen | 5 | 1995 | 60 | 0.510 |
Why?
| | Hyperkinesis | 1 | 2013 | 12 | 0.500 |
Why?
| | Diagnosis, Computer-Assisted | 1 | 2013 | 20 | 0.490 |
Why?
| | Humans | 16 | 2022 | 31481 | 0.480 |
Why?
| | Aged | 9 | 2022 | 10295 | 0.470 |
Why?
| | Middle Aged | 9 | 2020 | 11209 | 0.450 |
Why?
| | Adolescent | 4 | 2021 | 2667 | 0.420 |
Why?
| | Cognition Disorders | 1 | 2018 | 1075 | 0.400 |
Why?
| | Biomechanical Phenomena | 4 | 2022 | 719 | 0.390 |
Why?
| | Neuropsychological Tests | 4 | 2020 | 1300 | 0.390 |
Why?
| | Reference Values | 2 | 2021 | 260 | 0.390 |
Why?
| | Child | 3 | 2021 | 1572 | 0.370 |
Why?
| | Child, Preschool | 2 | 2021 | 786 | 0.340 |
Why?
| | Hippocampus | 4 | 1995 | 295 | 0.330 |
Why?
| | Adult | 5 | 2021 | 9779 | 0.330 |
Why?
| | Young Adult | 3 | 2021 | 2277 | 0.320 |
Why?
| | Cognition | 3 | 2020 | 1206 | 0.290 |
Why?
| | Parkinson Disease | 3 | 2020 | 1180 | 0.260 |
Why?
| | Shoes | 1 | 2022 | 29 | 0.220 |
Why?
| | Case-Control Studies | 2 | 2020 | 687 | 0.200 |
Why?
| | Pilot Projects | 2 | 2020 | 455 | 0.200 |
Why?
| | Spatio-Temporal Analysis | 1 | 2020 | 4 | 0.200 |
Why?
| | Time and Motion Studies | 1 | 2020 | 13 | 0.190 |
Why?
| | Foot | 1 | 2020 | 35 | 0.190 |
Why?
| | Glucosylceramidase | 1 | 2020 | 22 | 0.190 |
Why?
| | Retrospective Studies | 2 | 2020 | 3591 | 0.190 |
Why?
| | Arm | 1 | 2020 | 78 | 0.180 |
Why?
| | Range of Motion, Articular | 2 | 2020 | 703 | 0.170 |
Why?
| | Infusions, Spinal | 1 | 2018 | 4 | 0.170 |
Why?
| | Spinal Puncture | 1 | 2018 | 23 | 0.170 |
Why?
| | Mutation | 1 | 2020 | 464 | 0.160 |
Why?
| | Congresses as Topic | 1 | 2016 | 36 | 0.150 |
Why?
| | Brain Tissue Transplantation | 2 | 1993 | 26 | 0.150 |
Why?
| | Motor Activity | 1 | 2020 | 397 | 0.150 |
Why?
| | Posture | 1 | 2016 | 92 | 0.150 |
Why?
| | Animals | 7 | 2016 | 5312 | 0.150 |
Why?
| | Computers | 1 | 2015 | 26 | 0.140 |
Why?
| | Aged, 80 and over | 2 | 2016 | 5234 | 0.140 |
Why?
| | Trinucleotide Repeat Expansion | 1 | 2015 | 43 | 0.140 |
Why?
| | Early Diagnosis | 1 | 2015 | 76 | 0.140 |
Why?
| | Neuroimaging | 1 | 2016 | 126 | 0.140 |
Why?
| | Animals, Newborn | 3 | 1993 | 77 | 0.140 |
Why?
| | Reaction Time | 1 | 2015 | 128 | 0.140 |
Why?
| | Monitoring, Physiologic | 1 | 2015 | 100 | 0.140 |
Why?
| | Sexual Behavior, Animal | 1 | 1994 | 4 | 0.130 |
Why?
| | Receptors, Progesterone | 1 | 1994 | 36 | 0.130 |
Why?
| | Pituitary-Adrenal System | 1 | 1994 | 17 | 0.130 |
Why?
| | Regression Analysis | 1 | 2015 | 319 | 0.130 |
Why?
| | Hypothalamo-Hypophyseal System | 1 | 1994 | 29 | 0.130 |
Why?
| | Time Factors | 1 | 2020 | 1902 | 0.130 |
Why?
| | Arousal | 1 | 1994 | 56 | 0.130 |
Why?
| | Cerebral Cortex | 2 | 1993 | 206 | 0.130 |
Why?
| | Disability Evaluation | 1 | 2016 | 332 | 0.130 |
Why?
| | RNA, Messenger | 1 | 1995 | 371 | 0.130 |
Why?
| | Task Performance and Analysis | 1 | 2013 | 58 | 0.120 |
Why?
| | Cerebellar Diseases | 1 | 2013 | 11 | 0.120 |
Why?
| | Disease Progression | 1 | 2016 | 861 | 0.120 |
Why?
| | Rats | 6 | 1995 | 966 | 0.120 |
Why?
| | Movement | 1 | 2013 | 167 | 0.110 |
Why?
| | Activities of Daily Living | 1 | 2015 | 495 | 0.110 |
Why?
| | Neurons | 2 | 1995 | 407 | 0.100 |
Why?
| | Magnetic Resonance Imaging | 1 | 2016 | 1273 | 0.100 |
Why?
| | Cohort Studies | 1 | 2016 | 2014 | 0.100 |
Why?
| | Treatment Outcome | 1 | 2020 | 3910 | 0.100 |
Why?
| | Rats, Sprague-Dawley | 2 | 1995 | 494 | 0.060 |
Why?
| | Fetal Tissue Transplantation | 2 | 1993 | 34 | 0.060 |
Why?
| | Estradiol | 2 | 1993 | 68 | 0.060 |
Why?
| | Mechanical Phenomena | 1 | 2022 | 24 | 0.050 |
Why?
| | Pregnancy | 2 | 1993 | 457 | 0.050 |
Why?
| | Reproducibility of Results | 1 | 2022 | 886 | 0.040 |
Why?
| | alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid | 1 | 1995 | 1 | 0.040 |
Why?
| | N-Methylaspartate | 1 | 1995 | 4 | 0.040 |
Why?
| | Fibroblast Growth Factor 2 | 1 | 1995 | 24 | 0.040 |
Why?
| | Receptors, AMPA | 1 | 1995 | 13 | 0.040 |
Why?
| | Sex Differentiation | 1 | 1995 | 2 | 0.030 |
Why?
| | Blotting, Northern | 1 | 1995 | 29 | 0.030 |
Why?
| | DNA, Complementary | 1 | 1995 | 39 | 0.030 |
Why?
| | In Situ Hybridization | 1 | 1995 | 63 | 0.030 |
Why?
| | Corticotropin-Releasing Hormone | 1 | 1994 | 7 | 0.030 |
Why?
| | Adrenocorticotropic Hormone | 1 | 1994 | 11 | 0.030 |
Why?
| | Rats, Inbred Strains | 2 | 1992 | 46 | 0.030 |
Why?
| | Cytosol | 2 | 1992 | 61 | 0.030 |
Why?
| | Gene Expression | 1 | 1995 | 272 | 0.030 |
Why?
| | Preoptic Area | 1 | 1993 | 6 | 0.030 |
Why?
| | Transplantation, Heterotopic | 1 | 1993 | 13 | 0.030 |
Why?
| | Brain Mapping | 1 | 1994 | 199 | 0.030 |
Why?
| | Frontal Lobe | 1 | 1993 | 87 | 0.030 |
Why?
| | Cross-Sectional Studies | 1 | 2016 | 986 | 0.030 |
Why?
| | Gene Expression Regulation | 1 | 1994 | 351 | 0.030 |
Why?
| | Age Factors | 1 | 1995 | 943 | 0.030 |
Why?
| | Aging | 2 | 1993 | 1614 | 0.030 |
Why?
| | Calcium | 1 | 1995 | 519 | 0.030 |
Why?
| | Ethinyl Estradiol | 1 | 1990 | 2 | 0.030 |
Why?
| | Estrogen Antagonists | 1 | 1990 | 3 | 0.030 |
Why?
| | Chromatography, Affinity | 1 | 1990 | 11 | 0.030 |
Why?
| | Diethylstilbestrol | 1 | 1990 | 4 | 0.030 |
Why?
| | Cell Nucleus | 1 | 1990 | 90 | 0.020 |
Why?
| | Kinetics | 1 | 1990 | 278 | 0.020 |
Why?
| | Sex Factors | 1 | 1990 | 542 | 0.020 |
Why?
| | Receptors, Glutamate | 1 | 1995 | 4 | 0.010 |
Why?
| | Glutamic Acid | 1 | 1995 | 36 | 0.010 |
Why?
| | Receptors, N-Methyl-D-Aspartate | 1 | 1995 | 35 | 0.010 |
Why?
| | Cells, Cultured | 1 | 1995 | 802 | 0.010 |
Why?
| | Transplantation, Homologous | 1 | 1992 | 292 | 0.010 |
Why?
|
|
O'Keefe's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|